FEIBA® (anti-inhibitor coagulant complex)

FEIBA is authorized only for IV use to treat hemophilia A or B with inhibitors (control/prevention of bleeding, perioperative management, routine prophylaxis) and for treatment of bleeding in acquired hemophilia A (compendial), with all other uses excluded; authorization requires a hematologist/hemophilia specialist prescription or consultation, documented diagnosis/indication and dosing plan, dosing consistent with policy (50–100 units/kg for bleeding/perioperative; 85 units/kg every other day for prophylaxis), and is valid for up to 12 months.

"Hemophilia A with inhibitors — control and prevention of bleeding episodes (FDA-approved)"

Sign up to see full coverage criteria, indications, and limitations.